Get notified when TVTX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: TVTX Travere Therapeutics, Inc. 8-K

Travere names CMO Jula Inrig as Head of R&D following CRO retirement announcement

Filed June 16, 2026 · Period ending June 12, 2026 · ~1 min read

Key Changes

  • medium

    Chief Medical Officer Jula Inrig promoted to Executive Vice President, Head of Research & Development effective July 1, 2026, consolidating R&D leadership under one executive.

  • medium

    Chief Research Officer William Rote announced retirement effective February 17, 2027, marking his 10-year anniversary with Travere. He will continue in current role through retirement date.

  • low

    Company plans consulting arrangement with retiring CRO Rote to maintain access to his expertise following February 2027 departure.

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.

Partner

Trade TVTX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 16, 2026 5:06 PM